KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Taxes: 2021-2024

Historic Current Taxes for Moderna (MRNA) over the last 3 years, with Sep 2024 value amounting to $4.0 million.

  • Moderna's Current Taxes fell 92.86% to $4.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $4.0 million, marking a year-over-year decrease of 92.86%. This contributed to the annual value of $63.0 million for FY2023, which is 31.25% up from last year.
  • According to the latest figures from Q3 2024, Moderna's Current Taxes is $4.0 million, which was down 42.86% from $7.0 million recorded in Q2 2024.
  • In the past 5 years, Moderna's Current Taxes ranged from a high of $1.6 billion in Q1 2022 and a low of $4.0 million during Q3 2024.
  • Its 3-year average for Current Taxes is $213.6 million, with a median of $56.0 million in 2023.
  • The largest annual percentage gain for Moderna's Current Taxes in the last 5 years was 31.25% (2023), contrasted with its biggest fall of 95.85% (2023).
  • Moderna's Current Taxes (Quarterly) stood at $876.0 million in 2021, then crashed by 94.52% to $48.0 million in 2022, then spiked by 31.25% to $63.0 million in 2023, then slumped by 92.86% to $4.0 million in 2024.
  • Its last three reported values are $4.0 million in Q3 2024, $7.0 million for Q2 2024, and $52.0 million during Q1 2024.